Denosumab, a fully human monoclonal antibody that inhibits osteoclast-mediated bone resorption by targeting the receptor activator of nuclear factor-kappa B ligand (RANKL) pathway, has emerged as a promising adjunctive therapy for a spectrum of giant-cell-rich bone tumors. The gene discussed is TNFSF11; the disease is bone neoplasm.